Clinical trials: Neuroendocrine Tumor Metastatic
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer
Non-Viral TCR Gene Therapy
Background: A person s white blood cells can be modified in a lab to recognize certain changes in their tumor. Many of these cells are collected from the person, modified, then given back to the person.
- Conditions
- Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers
- Trial name
- NCT04102436
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Liver Tumors
Freehand Ultrasound Elasticity Imaging in Liver Surgery
The purpose of this study is to investigate the potential for visualizing radiofrequency-induced (RFA) and microwave-induced (MWA) hepatic thermal ablation lesions using a novel, high resolution, and freehand ultrasound…
- Trial name
- IOUS (NCT00942383)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma
Post-ATU Study of Nivolumab
Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015.
- Trial name
- Post-ATU (NCT03325257)
- Testing
- Routine care
- Where
- 17 sites in France
- Volunteers
- 350 people
- Sponsor
- Nantes University Hospital
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Melanoma (Skin Cancer)
Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma
This study is a retrospective, proof-of-concept sample study to investigate a novel histological finding within the primary melanoma tumour in a large population of melanoma patients to assess its prognostic significance.
- Trial name
- ROTATE (NCT07293598)
- Testing
- Sample analysis only
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- The Christie NHS Foundation Trust
Carcinoid Tumors
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Study evaluating SOM230 in patients with metastatic carcinoid tumors
- Trial name
- NCT00088595
- Testing
- Pasireotide (SOM230)
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in…
- Trial name
- NCT01876212
- Testing
- DC vaccine, Dasatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Walter J. Storkus
Melanoma
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC. Two question are aimed to be answered by this study: 1.
- Trial name
- ChemoSensMM (NCT00779714)
- Testing
- DTIC (dacarbazine), paclitaxel + cisplatin, treosulfan + cytarabine
- Where
- 23 sites in Germany
- Volunteers
- 360 people
- Sponsor
- University of Wuerzburg
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Cancer
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.
- Trial name
- NCT00613509
- Testing
- ALVAC(2) Melanoma multi-antigen therapeutic vaccine, Intron A, Interferon alpha -2b
- Where
- 19 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Neuroendocrine Tumors, Liver Metastases
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with…
- Trial name
- ILUMINET (NCT01456078)
- Testing
- 177Lu-DOTA-TATE
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Lund University Hospital
Melanoma Stage III, Melanoma Stage IV
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT03153085
- Testing
- TBI-1401(HF10), Ipilimumab
- Where
- 12 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Melanoma, Melanoma (Skin)
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
In the BRIM-3 trial, which was conducted in patients with previously untreated advanced melanoma harboring the BRAF V600E mutation, vemurafenib, a potent inhibitor of mutated BRAF, was associated with prolonged overall survival…
- Conditions
- Melanoma, Melanoma (Skin), Melanoma Stage
- Trial name
- VECODUE (NCT03224208)
- Testing
- Vemurafenib, Cobimetinib
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione Melanoma Onlus
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Cutaneous Melanoma
Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases
Electroporation is a method that can facilitate transport of molecules across the cell membrane and into the cell by means of electrical pulses.
- Trial name
- NCT03628417
- Testing
- Calcium Electroporation, Bleomycin based electrochemotherapy
- Volunteers
- 7 people
- Sponsor
- Szeged University
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or…
- Trial name
- MONETTE (NCT05061134)
- Testing
- Ceralasertib, Durvalumab
- Where
- 66 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.